초록접수 현황
| 15F-220 | 구연 발표 |
Survival Analysis Following Pulmonary Metastasectomy for Non-small Cell Lung Cancer
Hyo-Jun Jang, M.D.¹, Sungjoon Park, M.D.¹, Kyung wook Shin, M.D.¹, Eunjue Yi, M.D.¹, Sukki Cho, M.D., Ph.D.¹,², Sanghoon Jheon, M.D., Ph.D.¹,², Kwhanmien Kim, M.D., Ph.D¹,²
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Republic of Korea¹, Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea²
Background : The effectiveness of pulmonary metastasectomy for non-small cell lung cancer (NSCLC) is controversial. The aim of this study is to report the overall survival after pulmonary metastasectomy for NSCLC and to determine prognostic factors for survival.
Methods : Between June 2003 and July 2007, eighty seven cases underwent pulmonary resection for metachronous lung cancer in single center. Exclusions were following, pulmonary resection for metachronous primary lung cancer (23 cases), local regional recurrence (11 cases), recurrent pulmonary metastasis (9 cases) and lack of information (5 cases). 39 cases of first pulmonary metastsectomy in 39 patients were analyzed.
Results : There were 24 men and 15 women, and the mean age at pulmonary metastasectomy was 64.9 years. The median recurrence free time from initial pulmonary resection to pulmonary metastasectomy was 18.5 months. The overall 5-year survival rate was 69.2%. In multiivariate analysis, ager over 70 years (hazard ratio (HR) 5.38, 95% confidence interval (CI) ; 1.57-18.49, p=0.07) , non-adenocarcinoma (HR 5.44, 95% CI ; 1.42-20.82, p=0.13) and elevated CEA level (HR 6.19, 95% CI ; 1.36-28.12, p=0.18) were poor prognostic factors for overall survival. In patients with recurrence free time over 24 months, there was no death during follow up period. Gender, initial TNM stage, operation type of pulmonary metastasectomy, number and size of pulmonary nodule and distance from nodule to margin were not associated with overall survival.
Conclusion : Survival following pulmonary metastasectomy for NSCLC is acceptable. In selected patients, pulmonary metastasectomy for NSCLC may confer a good survival. It appears reasonable that such patients might be considered as surgical candidates.
Methods : Between June 2003 and July 2007, eighty seven cases underwent pulmonary resection for metachronous lung cancer in single center. Exclusions were following, pulmonary resection for metachronous primary lung cancer (23 cases), local regional recurrence (11 cases), recurrent pulmonary metastasis (9 cases) and lack of information (5 cases). 39 cases of first pulmonary metastsectomy in 39 patients were analyzed.
Results : There were 24 men and 15 women, and the mean age at pulmonary metastasectomy was 64.9 years. The median recurrence free time from initial pulmonary resection to pulmonary metastasectomy was 18.5 months. The overall 5-year survival rate was 69.2%. In multiivariate analysis, ager over 70 years (hazard ratio (HR) 5.38, 95% confidence interval (CI) ; 1.57-18.49, p=0.07) , non-adenocarcinoma (HR 5.44, 95% CI ; 1.42-20.82, p=0.13) and elevated CEA level (HR 6.19, 95% CI ; 1.36-28.12, p=0.18) were poor prognostic factors for overall survival. In patients with recurrence free time over 24 months, there was no death during follow up period. Gender, initial TNM stage, operation type of pulmonary metastasectomy, number and size of pulmonary nodule and distance from nodule to margin were not associated with overall survival.
Conclusion : Survival following pulmonary metastasectomy for NSCLC is acceptable. In selected patients, pulmonary metastasectomy for NSCLC may confer a good survival. It appears reasonable that such patients might be considered as surgical candidates.
책임저자: Kwhanmien Kim
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Republic of Korea
연락처 : Hyo-Jun Jang, Tel: 010-6362-6361 , E-mail : rgo38@naver.com
